Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc.

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORK, Jan. 14, 2021 -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chi... Read More...

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body NEW YORK, Jan. 12, 2021 -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced an innovative randomi... Read More...

Innovative Tennant Decorative Stone Slurry™ System by Tennant Coatings Elevates Epoxy Flooring with Groundbreaking Functional Benefits and New Luxury Look

CHICAGO, Jan. 11, 2021 -- Tennant Coatings, Inc., industry-leading manufacturer of commercial, institutional and industrial coating systems for concrete floors has launched the innovative new Tennant Decorative Stone SlurryTM System. This epoxy flooring advancement features a unique luxury aesthetic with stunning color saturation and stri... Read More...

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand

Bolsters Cash on Hand to CAD $183.0m (USD $144.4m)NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Jan. 7, 2021 -- Mind Medicine (MindMed) Inc. (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ) ("MindMed") is pleased to announce that it has closed its previously announced bought deal short for... Read More...

Four Top Psychedelic Stock Picks for 2021

The Top Companies Addressing Mental Health CrisisATLANTA, Jan. 04, 2021 -- 2020 was a banner year for investors in psychedelic companies as investors in Mind Medicine (MindMed) Inc. (OTCQB: MMEDF), 20/20 Global, Inc. (OTC: TWGL), Compass Pathways (NASDAQ: CMPS), and Numinus Wellness Inc. (OTC: LKYSF) saw their money triple and even quadru... Read More...

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy

Provides Clinical Development Update on 18-MCBased on positive pre-IND meeting with U.S. Food and Drug Administration (FDA), MindMed is now prepared to open an Investigational New Drug (IND) in August 2021 with a Phase 2b clinical trial for LSD assisted therapy in anxietyMindMed continues dose escalation of 18-MC in Phase I SAD/MAD; Meeti... Read More...

BakeMark Expands Sup-R-Shop™ Digital Platform

LOS ANGELES, Dec. 1, 2020 -- BakeMark announces the expansion of the best digital online ordering solution to the bakery community, Sup-R-Shop™. Online ordering, as an option, has been available to BakeMark customers since 2008."At BakeMark, we've always been focused on helping our customers succeed. We deliver unmatched service through o... Read More...

Statement from Huawei Canada

OTTAWA, ON, Nov. 19, 2020 - Antimicrobial resistance is a growing public health threat in Canada and worldwide. This is a global issue which requires global consideration and innovation.World Antimicrobial Awareness Week, from November 18-24, provides us with an opportunity to learn about the important actions we can take to maintain the ... Read More...

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

NEW YORK, Nov. 24, 2020 -- MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company r... Read More...

Statement from the Chief Public Health Officer of Canada – World Antimicrobial Awareness Week 2020

OTTAWA, ON, Nov. 19, 2020 - Antimicrobial resistance is a growing public health threat in Canada and worldwide. This is a global issue which requires global consideration and innovation.World Antimicrobial Awareness Week, from November 18-24, provides us with an opportunity to learn about the important actions we can take to maintain the ... Read More...

MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities

Project Lucy Submits Pre-IND Briefing Package to the FDA; Agrees Q1 Interim Analysis of Swiss Phase 2a Trial of LSD Assisted Therapy for Anxiety DisordersNEW YORK and BASEL, Switzerland, Nov. 16, 2020 -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has received a positive response on its ... Read More...

MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD

Data to Support MindMed's Project Lucy in Preparing Phase 2b Trial for Anxiety DisordersNEW YORK, Nov. 2, 2020 -- MindMed (NEO: MMED, OTCQB: MMEDF), the leading psychedelic medicine biotech company in partnership with University Hospital Basel's Liechti Lab announces the completion and publication of a Phase 1 study on the acute dose depe... Read More...

MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines

Post-Financing Cash Reserves of CAD $50.1m (USD $37.8m) to Enable Continued Advancement of Diverse and Growing Clinical Trial Pipeline of PsychedelicsNOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, Oct. 30, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) ("MindMed" o... Read More...

MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines

MindMed To Provide Funding for Psychedelic Medicine Research Training Program at NYU Langone Health and NYU Grossman School of Medicine NEW YORK, Oct. 5, 2020 -- MindMed (NEO: MMED) (OTCQB: MMEDF), the leading psychedelic medicine biotech company, on the heels of filing a NASDAQ uplisting application, today announced a funding commitment ... Read More...

MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

NEW YORK, Sept. 21, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market ("NASDAQ").Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))As ... Read More...

Mainstream Renewable Power Closes Second Phase of c.US$1.8 billion Wind and Solar Financing Deal in Chile

MindMed is funding a Phase 1 Clinical Trial at University Hospital Basel Liechti LabNEW YORK, Aug. 25, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines and the University Hospital Basel's Liechti Lab are now combining MDMA and LSD in a groundbreaking... Read More...

MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy

Applauds Health Canada's Approval Of Psilocybin Compassionate Access For PatientsNEW YORK, Aug. 6, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Pr... Read More...

MindMed Completes Dosing 18-MC Phase 1 Study

Company, seeing early success, will advance preparations for Phase 2a clinical trial in opioid addictionNEW YORK, July 28, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC. The dosing of 18-MC was well... Read More...

MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry

MindMed Co-founders and Co-CEOs JR Rahn and Stephen Hurst to provide corporate update of activities and investor Q&A on July 2, 2020 at 1pm EDT NEW YORK , June 26, 2020 -- MindMed, the leading neuro-pharmaceutical company for psychedelic inspired medicines is rapidly advancing its drug development pipeline and R&D activities since... Read More...

MindMed To Evaluate Ayahuasca’s Active Ingredient DMT In Phase 1 Clinical Trial Collaboration

Phase 1 Trial to experiment with dosing methods to better understand how humans react to DMT, setting stage for future potential Phase 2a proof of concept trialsBASEL, Switzerland, June 18, 2020 -- MindMed will now pursue N,N-Dimethyltryptamine (DMT), the principally active ingredient in Ayahuasca, as part of its R&D collaboration wit... Read More...

MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders

Targeting a Phase 2b psychedelic assisted therapy trial for the treatment of anxiety disordersNEW YORK, June 4, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, has officially launched Project Lucy, a commercial drug development program for the trea... Read More...

MindMed’s Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD

Adds Clinical Trial Site at University Hospital Basel and Appoints World Leading Psychedelics Researcher Dr. Matthias Liechti as Principal InvestigatorBASEL, Switzerland, June 2, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD. MindMed is the leading ... Read More...

MindMed Closes Upsized Financing of $13.2m to Advance UHB Liechti Lab Collaboration for Next-Gen Psychedelic Inspired Medicines

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO , May 26, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) ("MindMed" or the "Company") is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercis... Read More...

MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator

Signs Clinical Trial Agreement With Maastricht University In Netherlands NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO , May 12, 2020 -- Mind Medicine (MindMed) Inc. (NEO: MMED; OTC: MMEDF) ("MindMed" or the "Company") is pleased to announce that, on May 8, 2020 , it has entered ... Read More...